Compression of levocarnitine as a direct-compression tablet core exposes three processing constraints that are not resolved by a standard filler-binder system. Levocarnitine is a hygroscopic inner salt with a molecular weight of 161.2 g/mol and a compacted bulk density generally below 0.60 g/mL; at relative humidity above 40% at 25°C, surface moisture uptake accelerates punch filming. A direct-compression blend is prepared with levocarnitine at 60–80% w/w, microcrystalline cellulose PH-102 at 15–30% w/w, crospovidone at 2–4% w/w, colloidal silicon dioxide at 0.5–1.5% w/w, and sodium stearyl fumarate at 0.5–1.5% w/w. Each ingredient is sieved through a 0.710 mm screen and blended in a bin blender at 12–18 rpm for 15–25 min. On a 27-station rotary tablet press with D-tooling, precompression force is set at 5–8 kN and main compression at 15–25 kN; this range typically produces core hardness of 80–150 N and friability below 1.0% when tested per USP <1216>. Tablet disintegration is controlled to ≤30 min in water at 37°C per USP <701>. Dissolution testing uses USP <711> apparatus 2 at 50 rpm in 900 mL water; immediate-release levocarnitine tablets commonly require Q ≥80% at 30 min. The primary production failure on rotary presses is upper-punch sticking when granulation relative humidity exceeds 45%; therefore compression suites are held at 20–25°C and 35–40% RH with compressed-air punch cooling. Tablet cores are film-coated with a low-viscosity HPMC-based system using a 48-inch side-vented pan at 2–8 rpm to prevent edge erosion. The finished 330 mg and 500 mg levocarnitine tablets are used in primary and secondary carnitine deficiency and in renal dialysis patients.

What Limits Fill Weight Uniformity in Levocarnitine Capsule Filling?

In capsule filling, levocarnitine is governed less by chemical stability than by poor flow and low tapped density. Untreated levocarnitine powder can exhibit Carr index values above 30% and Hausner ratios above 1.35, placing it outside the free-flowing range required for dosator-based capsule machines. For a 250 mg capsule strength, direct filling is generally replaced by dry granulation in a roller compactor with roll pressure of 30–60 bar and screen milling through 0.8–1.0 mm mesh. The granulated material is blended with lactose monohydrate at a drug-to-diluent ratio of 1:0.7 to 1:1.5, pregelatinised starch as a disintegrant at 2–5% w/w, and magnesium stearate at 0.5–1.0% w/w. Fill weight is verified in-process at 10–20 min intervals on an automatic checkweigher; acceptance limits for hard gelatin or HPMC capsules follow USP <905> content uniformity and a process capability target of fill weight RSD ≤2.5%. When the powder-bed temperature rises above 30°C during prolonged filling, levocarnitine particles soften at contact points and begin to adhere to tamping pins, causing fill weight drift. This is controlled by maintaining encapsulation suite dew point below 7°C and by using polished tamping pins with a chromium nitride surface finish. The capsule product is packed with a silica gel desiccant in HDPE bottles because moisture ingress above 50% RH causes shell deformation and dissolution delay. The terminal use is oral carnitine replacement in metabolic disorders; the capsule shell dissolves within ≤15 min in 37°C water per USP <701>.

Terminal Sterilization Parameters for Levocarnitine Injection

Levocarnitine injection is supplied as a 200 mg/mL solution in single-dose vials; because the active is thermostable in aqueous solution, terminal sterilization is preferred over aseptic fill for sterile labelled product. The bulk solution is prepared with levocarnitine dissolved in water for injection, and the pH is adjusted with hydrochloric acid or sodium hydroxide to the approved registered range; pH is measured per USP <791> before and after sterilization. The solution is filtered through a 0.45 µm prefilter and a 0.22 µm sterilizing-grade polyvinylidene fluoride membrane before filling. Terminal sterilization is carried out in a water-cascade autoclave at 121°C for 15 min, with an F0 value of ≥15 min. After sterilization, filled units are tested for particulate matter per USP <788>, sterility per USP <71>, and bacterial endotoxins per USP <85>. Endotoxin limits are derived from the approved maximum dose and are conventionally expressed in EU per mg of levocarnitine; kinetic chromogenic LAL is used for release. Stability data indicate that pH drift of more than 0.5 units after terminal sterilization suggests buffer loss or container-liner interaction, and such lots are rejected. The injection is diluted in 0.9% sodium chloride or 5% dextrose before intravenous infusion. Filling and terminal sterilization are performed under EU GMP Annex 1 conditions with grade A environmental monitoring limits of ≤1 CFU/m³ and ≤3520 non-viable particles ≥0.5 µm per m³ at rest.

For renal clinics where fluid restriction is prescribed, levocarnitine is formulated as oral granules in unit-dose sachets rather than tablets or capsules. The granule formulation is produced by fluid-bed top-spray granulation using a binder solution of povidone K30 at 3–5% w/w in purified water; the bowl charge contains levocarnitine plus mannitol at a ratio of 1:0.5 to 1:0.8, with anhydrous citric acid at 0.5–1.5% w/w for dissolution pH adjustment. Spray rate is maintained at 20–50 g/min for a 60 L fluid-bed bowl, inlet air temperature at 50–60°C, and product temperature at 28–32°C. The dried granules are sieved to 0.2–1.0 mm and filled into aluminium-foil sachets under ≤25% RH. Each sachet commonly delivers 1.0 g levocarnitine; the content is dispersed in 100–200 mL water and administered as a single dose. Dissolution of the granules is tested by USP <711> apparatus 2 with 900 mL water at 50 rpm; release is ordinarily ≥85% at 15 min. The main stability defect is moisture-induced caking if the foil seal fails; sachets are therefore packed with molecular sieve desiccant and tested for seal integrity by dye penetration. Granule sachets provide the same terminal use of carnitine replacement in dialysis and inherited metabolic disease but avoid tablet-core hardness and capsule-shell degradation risks associated with high-humidity storage.

When Venetoclax Intermediate Acceptance Testing Drives Oral Tablet Supply Chain Quality

Venetoclax is an oral B-cell lymphoma-2 inhibitor formulated as film-coated immediate-release tablets; the supply chain for the API begins with intermediates whose residual impurity profile directly sets the final drug substance specification. Intermediates entering the final registered route are controlled under ICH Q11 for starting materials and process controls. Residual solvents are limited according to ICH Q3C option 1; for a class 2 solvent such as dichloromethane, the oral API limit is 600 ppm, and for class 3 solvents the total is 5000 ppm or 0.5% w/w. Elemental impurities are controlled per ICH Q3D; because venetoclax is an oral solid dose product, the drug product limit for palladium is based on a PDE of 100 µg/day, and the API control limit is derived from the maximum daily dose. Genotoxic impurities are assessed under ICH M7; the default threshold of toxicological concern is 1.5 µg/day for a lifetime regimen, and higher limits require duration-based justification. The tablet product is manufactured under high-potency containment because published occupational exposure limits for venetoclax are not available in all regions. Intermediate dispensing is performed in a negative-pressure isolator with HEPA exhaust and air change rate of ≥60 air changes per hour. Tablet compression of the final API is carried out in contained 27-station presses with split-valve transfer to prevent cross-contamination. Intermediate-to-API transfer is validated by surrogate powder tests per ISPE SMEPAC and by surface wipe limits derived from the PDE. The terminal dosage strengths are 10 mg, 50 mg, and 100 mg venetoclax film-coated tablets for once-daily oral administration in chronic lymphocytic leukaemia and acute myeloid leukaemia.

Amorphous Phase Stability Determines Dissolution in Venetoclax Tablet Cores

Published quantitative formulation data for the approved venetoclax immediate-release tablet core are limited; the following process boundaries are drawn from BCS class IV amorphous dispersion manufacture and must be confirmed against the approved NDA. For a 100 mg tablet with a core mass in the range of 400–600 mg, the active-to-excipient ratio is approximately 1:4 to 1:5 in developmental formulations. The tablet core is produced with an amorphous solid dispersion to overcome the low aqueous solubility of the crystalline free base; process parameters are set to maintain the amorphous state because recrystallization reduces dissolution below the registered target. Dissolution is tested in phthalate buffer at pH 4.5 and in phosphate buffer at pH 6.8 using USP <711> apparatus 2 at 75 rpm. The method may use sodium lauryl sulfate at 0.1–0.3% w/w to maintain sink conditions; release acceptance is based on multi-point sampling because single-point Q values do not discriminate amorphous-to-crystalline conversion. X-ray powder diffraction is used as a routine stability indicator to confirm the absence of crystalline venetoclax peaks in the dispersion. The tablet core is compressed with low compression force of 8–14 kN to avoid fracturing the vitrified dispersion and exposing crystalline nuclei. Post-compression hardness is controlled at 60–100 N; higher hardness can increase disintegration time beyond 30 min. Coated tablets are packaged in cold-form aluminium blisters with desiccant because moisture above 30% RH accelerates phase separation and recrystallization in the dispersion. The product is administered orally, and dissolution performance is linked to the low-solubility classification of venetoclax.